Boston Scientific backs notes with 101% redemption clause
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Boston Scientific Corporation (BSX) guarantees American Medical Systems Europe B.V.’s (AMS Europe) proposed euro-denominated floating-rate and fixed-rate senior notes. AMS Europe intends to use net proceeds, with other financing and cash on hand, for the cash consideration and fees for Boston Scientific’s proposed Penumbra acquisition; remaining proceeds may serve general corporate purposes. The offering is not conditioned on closing the acquisition.
Penumbra stockholders approved the acquisition on May 6, 2026; regulatory approvals and other closing conditions remain, and completion was expected in early 2027. At announcement, the purchase price was approximately $14.5 billion ($374 per share). If the acquisition is not completed by the applicable deadline, or AMS Europe notifies the trustee and paying agent that Boston Scientific will not pursue it, each fixed-rate series must be redeemed at 101% of principal, plus accrued and unpaid interest. The deadline is the later of January 14, 2027 (extendable under the merger agreement to no later than January 14, 2028) or, if applicable, five business days after a later agreed extension. The notes are senior unsecured obligations fully and unconditionally guaranteed by Boston Scientific; they are structurally junior to liabilities of other subsidiaries and effectively junior to secured debt.
Filing Explained
This preliminary supplement is marked subject to completion and says its information may change; the principal amounts, coupons, maturities and estimated net proceeds are blank, so it does not establish the offering’s size or financing cost.
Key Figures
Key Terms
Special Mandatory Redemption financial
senior unsecured obligations financial
structurally junior financial
EURIBOR financial
Change of Control Repurchase Event financial
Actual/360 financial
Offering Details
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What happens to BSX fixed-rate notes if the Penumbra deal does not close?
How will AMS Europe use proceeds from its notes offering?
AI-generated analysis. How Rhea-AI works. Not financial advice.
(To Prospectus dated February 18, 2025)
€ % Senior Notes due 20
€ % Senior Notes due 20
€ % Senior Notes due 20
€ % Senior Notes due 20
€ % Senior Notes due 20
Boston Scientific Corporation
| | | |
Offering Price
to Public(1) |
| |
Underwriting
Discounts |
| |
Proceeds to AMS Europe
Before Expenses |
| |||||||||
|
Per Floating Rate Note
|
| | | | % | | | | | | % | | | | | | % | | |
|
Floating Rate Notes Total
|
| | | € | | | | | € | | | | | € | | | |||
|
Per 20 Note
|
| | | | % | | | | | | % | | | | | | % | | |
|
20 Notes Total
|
| | | € | | | | | € | | | | | € | | | |||
|
Per 20 Note
|
| | | | % | | | | | | % | | | | | | % | | |
|
20 Notes Total
|
| | | € | | | | | € | | | | | € | | | |||
|
Per 20 Note
|
| | | | % | | | | | | % | | | | | | % | | |
|
20 Notes Total
|
| | | € | | | | | € | | | | | € | | | |||
|
Per 20 Note
|
| | | | % | | | | | | % | | | | | | % | | |
|
20 Notes Total
|
| | | € | | | | | € | | | | | € | | | |||
|
Per 20 Note
|
| | | | % | | | | | | % | | | | | | % | | |
|
20 Notes Total
|
| | | € | | | | | € | | | | | € | | | |||
| Total | | | | € | | | | | € | | | | | € | | | | ||
| | Barclays | | |
Citigroup
|
| |
J.P. Morgan
|
|
| | | | |
BofA Securities
|
| | | |
| | | |
Page
|
| |||
|
ABOUT THIS PROSPECTUS SUPPLEMENT
|
| | | | S-ii | | |
|
STABILIZATION
|
| | | | S-iv | | |
|
NOTICE TO PROSPECTIVE INVESTORS IN THE EUROPEAN ECONOMIC AREA
|
| | | | S-v | | |
|
NOTICE TO PROSPECTIVE INVESTORS IN THE UNITED KINGDOM
|
| | | | S-v | | |
|
SUMMARY
|
| | | | S-1 | | |
|
RISK FACTORS
|
| | | | S-8 | | |
|
INFORMATION CONCERNING FORWARD-LOOKING STATEMENTS
|
| | | | S-16 | | |
|
USE OF PROCEEDS
|
| | | | S-17 | | |
|
DESCRIPTION OF THE NOTES
|
| | | | S-18 | | |
|
MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES
|
| | | | S-34 | | |
|
CERTAIN ERISA CONSIDERATIONS
|
| | | | S-39 | | |
|
CERTAIN DUTCH TAX CONSIDERATIONS
|
| | | | S-41 | | |
|
UNDERWRITING
|
| | | | S-45 | | |
|
LISTING AND GENERAL INFORMATION
|
| | | | S-51 | | |
|
LEGAL MATTERS
|
| | | | S-53 | | |
|
EXPERTS
|
| | | | S-53 | | |
|
WHERE YOU CAN FIND MORE INFORMATION
|
| | | | S-54 | | |
| | | |
Page
|
| |||
|
ABOUT THIS PROSPECTUS
|
| | | | 1 | | |
|
WHERE YOU CAN FIND MORE INFORMATION
|
| | | | 2 | | |
|
FORWARD-LOOKING STATEMENTS
|
| | | | 3 | | |
|
RISK FACTORS
|
| | | | 4 | | |
|
BOSTON SCIENTIFIC CORPORATION
|
| | | | 5 | | |
|
AMERICAN MEDICAL SYSTEMS EUROPE B.V.
|
| | | | 5 | | |
|
USE OF PROCEEDS
|
| | | | 6 | | |
|
DESCRIPTION OF DEBT SECURITIES
|
| | | | 7 | | |
|
PLAN OF DISTRIBUTION
|
| | | | 19 | | |
|
LEGAL MATTERS
|
| | | | 21 | | |
|
EXPERTS
|
| | | | 21 | | |
|
Underwriters
|
| |
Aggregate
Principal Amount of the Floating Rate Notes |
| |
Aggregate
Principal Amount of 20 Notes |
| |
Aggregate
Principal Amount of 20 Notes |
| |
Aggregate
Principal Amount of 20 Notes |
| |
Aggregate
Principal Amount of 20 Notes |
| |
Aggregate
Principal Amount of 20 Notes |
| ||||||||||||||||||
|
Barclays Bank PLC
|
| | | € | | | | | € | | | | | € | | | | | € | | | | | € | | | | | € | | | ||||||
|
Citigroup Global Markets Europe AG
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|
J.P. Morgan SE
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|
BofA Securities Europe SA
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Total | | | | € | | | | | € | | | | | € | | | | | € | | | | | € | | | | | € | | | | |||||
|
Name of Director
|
| |
Function
|
|
| Emily Woodworth | | | Managing Director | |
| Carla Madrid Magalhães Nascimbeni | | | Managing Director | |
300 Boston Scientific Way
Marlborough, Massachusetts 01752-1234
Attention: Investor Relations
Telephone: (508) 683-5670
Email: BSXInvestorRelations@bsci.com
Subordinated Debt Securities
Guarantees
Subordinated Debt Securities
Guarantees
| | | |
Page
|
| |||
|
ABOUT THIS PROSPECTUS
|
| | | | 1 | | |
|
WHERE YOU CAN FIND MORE INFORMATION
|
| | | | 2 | | |
|
FORWARD-LOOKING STATEMENTS
|
| | | | 3 | | |
|
RISK FACTORS
|
| | | | 4 | | |
|
BOSTON SCIENTIFIC CORPORATION
|
| | | | 5 | | |
|
AMERICAN MEDICAL SYSTEMS EUROPE B.V.
|
| | | | 5 | | |
|
USE OF PROCEEDS
|
| | | | 6 | | |
|
DESCRIPTION OF DEBT SECURITIES
|
| | | | 7 | | |
|
PLAN OF DISTRIBUTION
|
| | | | 19 | | |
|
LEGAL MATTERS
|
| | | | 21 | | |
|
EXPERTS
|
| | | | 21 | | |
300 Boston Scientific Way
Marlborough, Massachusetts 01752-1234
Attention: Investor Relations
Telephone: (508) 683-5670
Email: BSXInvestorRelations@bsci.com